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Abstract
Goals—Investigate the role of self-efficacy during HCV treatment.
Background—Adherence to chronic hepatitis C virus (HCV) treatment is critical. Self-efficacy 
(SE) is an important predictor of medication adherence in a number of chronic disease populations 
and medication regimens, but its role during HCV treatment remains unknown.
Study—Data from the prospective Virahep-C study was analyzed to examine relationships 
between SE and patient-driven deviations (i.e., missed doses measured using electronic pill caps, 
and nonpersistence) from adherence to HCV antiviral treatment. SE was measured using the 17-
item HCV Treatment Self-Efficacy scale. This measure provides a global estimate of a patient’s 
confidence to undergo and adhere to HCV treatment, and can estimate SE in four underlying 
domains: communication SE (i.e., confidence to communicate with healthcare provider), physical 
coping SE (i.e., confidence to cope with physical side effects), psychological coping SE (i.e., 
confidence to cope with psychiatric side effects), and treatment adherence SE (i.e., confidence to 
take all medication as prescribed and attend doctor visits). Generalized estimating equations and 
Cox proportional hazards models were used to assess associations between SE and missed doses 
and nonpersistence, respectively.
Results—SE was associated with being in a relationship, educated, privately insured, and less 
depressed. Higher communication SE at TW24 reduced the risk of missed doses between TW24 
and 48. Higher baseline treatment adherence SE reduced the likelihood of nonpersistence between 
baseline and TW24.
Corresponding Author: Donna M. Evon, Ph.D., Division of Gastroenterology and Hepatology, CB# 7584, 8010 Burnett-Womack, 
University of North Carolina, Chapel Hill, NC 27599, Telephone: (919) 966-6732, donna_evon@med.unc.edu, Fax: (919) 966-1700. 
Conflict of Interest Statement: Donna M. Evon received research grant support from Roche, and served as an ad hoc consultant to 
Vertex in the past 12 months. All other authors have nothing to disclose.
NIH Public Access
Author Manuscript
J Clin Gastroenterol. Author manuscript; available in PMC 2016 January 01.
Published in final edited form as:






















Conclusions—Self-efficacy’s relationship to HCV treatment adherence has promising clinical 
and research implications.
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Introduction
Chronic hepatitis C viral (HCV) infection is estimated to affect 2% of the United States 
adult population and is responsible for over 10,000 deaths annually 1, 2. While the incidence 
of acute HCV infections in the U.S. has decreased dramatically, the individual and public 
health burdens of chronic HCV are expected to rise over the next 20–30 years 3. Fortunately, 
antiviral medical regimens are available which can cure HCV and reduce mortality and 
morbidity 4. Historically, the backbone of these regimens was pegylated interferon (IFN) 
and ribavirin (RBV), which induced several severe treatment-related side effects (e.g., flu-
like, fatigue, anemia, insomnia, nausea, depression, and irritability), making adherence to 
the medical regimen a significant challenge. New developments in antiviral therapy, 
beginning with protease inhibitors (i.e., “triple therapy”) have become the standard of care, 
yet introduced more complex dosing schedules, additional side effects, and the potential for 
viral resistance in the presence of sub-optimal medication adherence 4, 5. Given the 
treatment-related side effects and complex dosing regimen of the current antiviral treatments 
for HCV, patients’ capacities to take multiple medications as prescribed, as well as their 
abilities to persist to the end of the treatment course, is paramount to treatment success.
Previous research has demonstrated that HCV patients need to be maintained on at least 
80% of IFN and 80% of ribavirin, for at least 80% of the treatment duration (24 or 48 
weeks) to maximize their chance of achieving a sustained virological response (SVR) (i.e., 
“cure”) 6. However, medically-necessary deviations, such as dose reductions and premature 
treatment discontinuations due to dangerous side effects, and patient-initiated deviations, 
such as missing doses or stopping treatment early due to unpleasant, but not life-threatening 
side effects, can interfere with achievement of the 80/80/80 standard and attenuate the 
chance of cure. Of the patient-driven deviations, how well patients take their medications as 
prescribed (referred to as “medication adherence” or “execution of dosing” in the broader 
health behavior literature) can affect treatment success 4, 7–9. In addition, persistence, or the 
total duration of time a patient takes their medication from first to last dose, can be 
significantly shortened. Patients may discontinue treatment earlier than recommended due to 
factors, such as intolerance to unpleasant side effects, noncompliance with treatment 
protocols, dropout, and patient preference 4, 7, 8.
The extent to which patients miss doses (i.e., medication nonadherence) of IFN/RBV during 
HCV treatment has been examined in only a handful of studies using self-report, pharmacy 
refill data, pill counts, and electronic monitoring caps 6, 10–16. Collectively, these studies 
show that (a) patients miss doses, particularly the twice daily oral RBV tablets; (b) the 
proportion of missed doses increases over time; and (c) missed doses are associated with 
worse virological response to treatment. Less is known about nonpersistence on IFN/RBV 
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treatment, defined as patient-driven premature treatment discontinuations. A recent study 
identified several unmodifiable sociodemographic characteristics (e.g., age, race, education 
level, insurance status, marital status) associated with missing doses or nonpersistence 
during HCV treatment, highlighting specific patient cohorts that may benefit from additional 
support 16. However, it is important to identify additional predictors of missed doses and 
nonpersistence which may be modifiable through behavioral or psychological interventions.
Identifying predictors to explain how and why patients missed doses and do not persist on 
medication has relatively unstudied in the HCV population 4. Internal attitudes, such as self-
efficacy or confidence in one’s ability to mobilize internal and/or external resources to 
engage in specific goal-directed behaviors, have been the focus of empirical and theoretical 
exploration across myriad health behaviors and medical conditions17, 18. However, self-
efficacy’s relationship to missed doses and nonpersistence in the context of HCV treatment 
has yet to be explored 19. While self-efficacy’s relationship to missed doses and 
nonpersistence is largely unknown in the HCV population, its role in adherence to 
medications for other chronic disease treatment, including the HIV population, has been 
explored. From the HIV literature, higher levels of self-efficacy lead to fewer missed doses, 
lower depressive symptoms, increased problem-solving abilities, and improved patient-
provider interactions during HIV treatment 20–22. Therefore, it is plausible that HCV 
patients who have higher levels of self-efficacy during HCV treatment will miss fewer doses 
than those with low self-efficacy. While no published studies have examined self-efficacy as 
a predictor of nonpersistence to HCV regimens, one might expect that higher levels of self-
efficacy serve to enable individuals to persevere through an arduous and unpleasant 
treatment with multiple side effects, consistent with the self-efficacy construct and evidence 
found in the broader health behavior literature 23–26.
Study Aims
The present study is the first empirical analysis of self-efficacy and adherence to HCV 
antiviral therapy. This study’s aims were two-fold. First, we sought to identify relationships 
between patient characteristics and self-efficacy before and during HCV treatment. We were 
interested specifically in self-efficacy’s relationship with other sociodemographic 
characteristics found previously in the literature to predict missed doses and 
nonpersistence 16. We were also interested in potential interactions between depression and 
self-efficacy, since this relationship exists in the literature in other chronic conditions and 
patients with HCV commonly suffer from premorbid or treatment-induced depression 27, 28. 
Second, we sought to determine whether self-efficacy predicted missed doses or 
nonpersistence during HCV treatment. To further expand on this second aim, we examined 
interactions between self-efficacy and age, gender, and depressive symptomatology, as 
evidence in the HIV literature suggests that relationships among these factors may affect 
self-management behaviors necessary to adhere to treatment regimens 29–31.
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The present study is a secondary data analysis of data from the NIH-funded Viral Resistance 
to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) study. Virahep-C was a 
multicenter, prospective, longitudinal study designed to evaluate factors that may explain 
racial disparities in SVR rates 11. The study enrolled African American (n=196) and 
Caucasian (n=205) patients with HCV genotype 1 across eight U.S. medical centers. All 
participants were new to HCV treatment. Virahep-C had many exclusion criteria, but 
included: (a) severe psychiatric disorders within the past 6 months including severe 
depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or 
personality disorder; (b) psychiatric hospitalization or suicide attempt within last 5 years; 
and (c) evidence of substance abuse (drugs or alcohol) in past 6 months. Participants 
engaged in a protocol-based treatment that consisted of weekly self-injections of IFN and 
twice daily dosed RBV tablets. All patients were treated for at least 24 weeks. Per study 
protocol, participants with undetectable HCV viral load at week 24 of treatment (“TW24 
Responders”) were continued on treatment for an additional 24 weeks, while those with 
detectable viral load at week 24 were discontinued from treatment per the study protocol 
(“Nonresponders”). Specific guidelines regarding discontinuation of treatment are detailed 
in the Virahep-C protocol on file at the National Institute of Diabetes and Digestive and 
Kidney Diseases Central Repository: https://www.niddkrepository.org/static/studies/
virahep-c/protocol/VirahepC_Protocol.pdf. Since the goal of Virahep-C was to investigate 
factors associated with treatment efficacy, maximizing adherence to the treatment protocol 
was essential. Therefore, an extensive Patient Education and Adherence Program was 
administered throughout the study to encourage medication adherence and side effect 
management for all participants. This program used structured interactions with study 
personnel to help participants enhance self-management for the duration of the study 
protocol. Virahep-C participants provided written informed consent and the study was 
approved by the respective Institutional Review Boards of participating research sites. 
Complete details about the Virahep-C study can be found at https://
www.niddkrepository.org/studies/virahep-c/.
Measures
Baseline Sociodemographic Characteristics—In the present study, 
sociodemographic variables of interest included age, gender, race, marital status, education 
level, employment status, and health insurance status.
HCV Treatment Self-efficacy Survey—The original self-efficacy instrument used in 
Virahep-C was a 24-item measure developed for the Adult AIDS Clinical Trials Group 
(AACTG), which was modified for use with individuals undergoing HCV treatment. A 
recent factor analysis of the instrument led to refining the measure into a 17-item scale that 
yielded a Global Self-Efficacy scale (GSE) and four self-efficacy subscales: (a) 
communication SE (i.e., confidence to communicate with healthcare provider); (b) physical 
coping SE (i.e., confidence to cope with physical side effects of treatment); (c) 
psychological coping SE (i.e., confidence to cope with emotional side effects of treatment); 
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and (d) treatment adherence SE (i.e., confidence to take all medication as prescribed and 
attend doctor visits) (See Table 1)19. The revised HCV Treatment Self-Efficacy Survey 
demonstrated good reliability for the GSE and the four subscales (Cronbach’s α range = .85 
to .96) and good discriminant validity with other psychosocial measures 19. Higher scores on 
each scale indicate higher levels of self-efficacy. In the Virahep-C protocol, self-efficacy 
was measured only at baseline and treatment week 24.
Depression—Depression was measured using the Center for Epidemiologic Studies–
Depression (CES-D) scale, a 20-item self-report measure 32. Items range from 0 (never) to 3 
(almost always), with total scores ranging from 0 to 60. Higher scores indicate more 
depressive symptomatology. In the present study, accepted cutoffs of <16 (no depressive 
symptomatology, referred to as “No Depression” or “None”), 16–22 (possible depression, 
referred to as “Mild-to-Moderate”), and ≥ 23 (probable depression, referred to as “Severe”) 
were used for categorical comparisons and analyses 28, 32. The CES-D was measured at 
multiple time points during the Virahep-C study, but for these analyses, we focused on 
measurement conducted at baseline and treatment week 24, concurrent with measurement of 
self-efficacy.
Adherence—The present study focused on two patient-driven deviations from the 
prescribed HCV treatment protocol: missed doses and treatment nonpersistence.
Missed Doses: While HCV treatment includes weekly injections of IFN and daily oral 
RBV, we chose to focus only on RBV in the present study. Previous research indicates that 
(a) patients miss a greater proportion of daily RBV compared to weekly IFN injections; (b) 
HCV treatment regimens currently in development are all-oral, IFN-free that includes 
combinations with RBV; and (c) decrements in RBV exposure, rather than IFN, may play a 
more critical role in nonresponse to HCV treatment in individuals naïve to 
treatment 5, 10, 12, 33. Missed doses of RBV were measured using Medication Event 
Management System (MEMS) caps (AARDEX Group Ltd., Switzerland). MEMS caps use a 
computer chip in the cap of a medication vial to record the precise date and time the vial was 
opened and presumably, when the medication was taken. When used properly, MEMS has 
been shown to be a valid, sensitive, specific representation of dose-taking behavior 16. 
MEMs data were downloaded at each study visit by study coordinators. Patients were fully 
trained in the correct use of the MEMS caps at baseline and throughout the study. Missed 
doses were defined as deviations from the number of RBV doses prescribed on a daily basis 
(0,1, or 2 doses taken by the participant out of a total number of doses prescribed [up to 2 
doses of RBV per day]) based on MEMS cap openings 16. If a participant was instructed by 
a provider to discontinue RBV for a period of time (or change the number of doses), and 
they did not open the MEMS cap during the appropriate periods of time, they were 
considered adherent to the study protocol (i.e., it was not counted as a missed dose). Time 0 
(first day of treatment) was excluded for all participants. In the present study, we analyzed 
missed RBV doses during two time periods: baseline to week 24 (n=384) and week 24 to 48 
in TW24 Responders only (n=170).
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Nonpersistence: Nonpersistence was defined as the time to patient-driven premature study 
or medication discontinuation at any time during the study, excluding virological 
nonresponse to treatment 16. Reasons for patient-driven discontinuation of study or 
medications included: intolerance to side effects; patient preference; nonadherence to study 
protocol; drop out (withdrawal); or refusal 16. Medically (rather than patient)-driven 
treatment discontinuations due to life-threatening lab abnormalities or medical conditions 
were censored from these analyses. In the present study, we analyzed nonpersistence events 
during two time periods: baseline to week 24 (n=384) and week 24 to 48 in TW24 
Responders only (n=170).
Statistical Analysis
Descriptive statistics included the median and interquartile range (IQR) for the baseline and 
TW24 measures of self-efficacy. Differences in the distribution of GSE score across 
categorical patient characteristics were assessed using a Wilcoxon rank sum (2 categories) 
or Kruskal-Wallis (3 categories) test, as appropriate. Post-hoc comparisons of Kruskal-
Wallis tests were adjusted using the Bonferroni method. Spearman’s rank correlation was 
used to examine relationships between continuous patient characteristics (e.g., CES-D) and 
GSE. Non-parametric methods were used due to the non-normal distribution of GSE scores 
(i.e., GSE scores tended to be negatively skewed).
The primary exposure of interest for both measures of adherence was the GSE score. We 
were interested in both the main effect on missed doses and nonpersistence, as well the 
possible effect of the interactions of GSE and age, gender, and CES-D score. We used 
baseline GSE (n=384) to predict missed doses and nonpersistence from baseline to week 24, 
and TW24-GSE to predict missed doses and nonpersistence among TW24 Responders 
(n=170) from weeks 24 to 48. For reasons unknown, 5 participants had missing baseline 
self-efficacy measures, and 71 participants who were TW24 Responders had missing TW24 
self-efficacy data. These participants were not included in this study’s TW24 analyses. We 
compared baseline patient characteristics and self-efficacy scores between those with 
(n=165) and without (n=71) TW24 self-efficacy to determine if any differences existed. 
Patients who were missing TW24 self-efficacy data had higher baseline GSE scores, higher 
physical coping and psychological coping self-efficacy scores, and lower baseline CES-D 
scores. However, these CES-D scores (for both those with and without TW24 GSE data) 
were mostly within the no depression (CES-D < 16) range.
Predicting Missed Doses—Generalized estimating equations (GEE) with a multinomial 
distribution and cumlogit link function were used to estimate odds ratios (OR) and 95% 
confidence intervals (CI) of missing more RBV doses (i.e., 2 doses missed vs. 1 and 0 doses 
missed, and 1 and 2 doses missed vs. 0 doses missed). Both unadjusted models and models 
adjusted for age, race, gender, insurance status, marital status, employment status, and CES-
D (baseline CES-D for baseline to week 24, and week 24 CES-D for weeks 24 to 48) were 
run for the baseline sample and the TW24 Responders. These covariates were selected a 
priori based on the empirical literature of factors related to missed doses/nonpersistence in 
HCV 16, as well as factors that predict or confound the relationship with medication 
adherence to HIV treatment 29–31, 34, 35.
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Predicting Nonpersistence—A Cox proportional hazards model was used to estimate 
hazard ratios (HR) for time to nonpersistence. Due to the small number of nonpersistence 
events from treatment weeks 24 to 48 (n=13), we were only able to analyze the baseline to 
week 24 data. Models were adjusted for the same a priori covariates as selected for missed 
doses analyses.
Statistical significance was established at 0.05 for main effects and 0.10 for interaction 
effects. In addition, using the same methodology, we analyzed the four self-efficacy 
subscales as predictors of missed doses and nonpersistence. No formal corrections were 
made for multiple testing of these subscales, as these were only exploratory in nature; 
however, we were conservative in our interpretation of these findings. All analyses were 
carried out using SAS version 9.2 (Cary, NC).
Results
Patient Characteristics Associated with Self-Efficacy
Patient characteristics of the full Virahep-C (n=401) study cohort are described 
elsewhere 11. The overall sample’s baseline median GSE score was 8.7 out of 10 (IQR: 7.8–
9.5) and TW24 median GSE was 8.3 (IQR: 7.0–9.3). The distribution of GSE scores across 
patient characteristics for baseline and TW24 are summarized in Table 2. Three-way post-
hoc comparisons revealed that participants with higher baseline self-efficacy scores were in 
a relationship and privately insured (p’s<0.001). Among TW24 Responders, GSE at TW24 
was higher among those married/partnered compared to divorced/widowed/separated 
(p<0.001) and privately insured compared to publicly insured individuals (p=0.004).
Self-Efficacy and Depressive Symptomatology—GSE at baseline was higher among 
those with no depressive symptoms compared to those with mild-to-moderate (p<0.001) or 
severe (p<0.001) symptoms (Figure 1). The difference in baseline GSE between mild-to-
moderate and severe depressive symptoms at baseline did not reach statistical significance 
(p=0.0168) due to Bonferonni correction for multiple comparisons (α=0.0167). Likewise, 
differences at TW24 between no depressive symptoms and mild-to-moderate (p=0.057), and 
mild-to-moderate to severe (p=0.052) did not reach statistical significance after Bonferonni 
correction, although TW24 GSE was higher in those with no depressive symptoms at TW24 
compared to those with severe depressive symptoms (p<0.001). Correlational analyses 
revealed a negative relationship between baseline depressive symptoms (continuous CES-D 
score) and the baseline GSE score (rs= − 0.62, p<0.001, n=384). This relationship was 
similar between TW24 CES-D and TW24 GSE (rs= − 0.50, p<0.001, n=165).
Self-Efficacy and Missed Doses
Missed doses of RBV increased over time: on average, participants missed 15% of doses by 
TW24 and 25% of doses by treatment week 48 (TW48). As noted in Table 3, there was no 
association between GSE and missed doses of RBV, either from baseline to TW24 or among 
TW24 Responders from week 24 to 48. In exploratory analyses of the four subscales, we 
only found statistically significant interactions for TW24 communication SE among 
Responders from TW24 to TW48. Specifically, interactions between TW24 communication 
Bonner et al. Page 7






















SE and gender (p=0.001) and CES-D (p=0.024) were associated with missing doses of RBV, 
even after adjusting for age, race, insurance status, marital status, and employment status. 
That is, after controlling for all other covariates, as communication SE increased, the odds of 
missing doses increased at a higher rate for women (OR=45.4; 95% CI: 4.11, 501.6) 
compared to men (OR=1.41; 95% CI: 0.92, 2.16). Due to the lack of precision in this finding 
(e.g., CI width of almost 500 for women), we give little weight to these point estimates. 
Similarly, the association between higher communication SE and missing fewer doses was 
greater in severely depressed individuals (e.g., CES-D≥23; OR=0.13; 95% CI: 0.01, 1.16) 
compared to mild to moderately depressed individuals (e.g. CES-D=16–22; OR=0.27; 95% 
CI: 0.05, 1.32).
Self-Efficacy and Nonpersistence
Although it appeared that GSE and three of the four subscales were associated with 
nonpersistence from baseline to week 24, only the relationship between nonpersistence and 
the treatment adherence SE subscale remained statistically significant (p=0.013) after 
adjusting for covariates (Table 4). This finding suggested that risk of nonpersistence was 
lower among participants who had higher levels of adherence self-efficacy at baseline. 
Although not statistically significant after adjusting for covariates, the relationship between 
baseline GSE and nonpersistence approached statistical significance (p=0.078).
Discussion
When patients deviate from the prescribed treatment regimens for HCV, such as missing 
doses of medication or failing to persist to the end of the treatment course, treatment 
response and cure rates are comprised 4, 6, 10, 36. Research into understanding which patient 
factors may be related to and possibly influence missed doses and nonpersistence during 
HCV treatment is in its infancy 4, 16. The present study sought to address this gap by 
exploring the relationship between the well-known construct of self-efficacy, and missed 
doses (i.e., “medication adherence”) and nonpersistence, which while investigated in other 
medical populations and treatments, had not been applied in the setting of HCV treatment.
In this large prospective study sample, participants’ overall confidence in their ability to 
undergo HCV treatment was fairly high, however, higher self-efficacy ratings were found 
among certain subgroups, such as those who were in a relationship, better educated, 
employed, or privately insured. Considerable differences were noted between level of 
depressive symptoms and global self-efficacy. Participants with greater depressive 
symptoms at baseline tended to be less confident in their ability to engage in HCV 
treatment. This was true at baseline and for TW24 Responders. This relationship is clinically 
relevant, first because depressive symptoms are common among patients diagnosed with 
HCV, are induced by IFN treatment, and can be related to worse treatment 
outcomes 27, 28, 37. Second, among patients with HIV, depressive symptoms predict both 
lower adherence self-efficacy and self-reported medication adherence, and the prediction of 
self-reported adherence by depressive symptoms has been shown to be at least partially 
mediated by adherence self-efficacy beliefs. 31, 38. In the parent study, researchers were 
blinded to both CES-D and GSE scores throughout the study, and so could not have acted 
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upon these differences. However, these findings suggest that the relationship between self-
efficacy, depression, and adherence in HCV may be a critical target for future clinical and 
research investigation to help in the clinical management of patients’ medication adherence 
and ability to persevere to the end of treatment.
Contrary to our expectations, neither baseline nor TW24 GSE predicted missed RBV doses. 
There are several possible reasons for the lack of association between GSE and missed 
doses, but perhaps the most salient is the purpose and study design of the parent study. The 
Patient Education and Adherence intervention was delivered to all participants from baseline 
to the end of treatment and may have bolstered patients’ confidence to ensure optimal 
adherence. Also, patients across the board had high levels of GSE at baseline and week 24, 
suggesting the possibility of a ceiling effect. Perhaps the high self-efficacy scores were due 
to fairly rigorous exclusion criteria and patient selection for those who were judged most 
likely to adhere to the treatment protocol. Finally, it may simply be that confidence in one’s 
ability to undergo HCV treatment is unrelated to missing doses in HCV, although this would 
be inconsistent with studies in HIV and other chronic illnesses which have found a stable, 
prospective relationship between self-efficacy and medication adherence 22, 31, 38. 
Interestingly, among TW24 Responders, higher confidence in one’s ability to communicate, 
discuss issues, and work out difficulties with clinicians served as a protective factor against 
missing RBV doses in those individuals who experienced severe depressive symptoms at 
TW24. This finding suggests that even among individuals experiencing significant 
depressive symptoms, greater confidence in one’s ability to communicate with a medical 
provider could buffer patients from poorer outcomes during HCV treatment.
Only baseline treatment adherence self-efficacy predicted nonpersistence between baseline 
and treatment week 24. Individuals who reported greater confidence in taking their 
medications exactly as prescribed, attending follow-up clinic visits, and doing so despite 
feeling fatigued or depressed, were less likely to drop out of treatment early 4. These 
findings suggest that clinicians should consider monitoring adherence self-efficacy and 
intervening when appropriate to bolster confidence levels to help patients persevere through 
a difficult treatment course.
Strengths of the present study include a large sample size, rigorous prospective study design, 
measurement of medication adherence using objective electronic monitoring technology, 
and use of an psychometrically sound measure of HCV treatment self-efficacy 19. However, 
a few limitations are noted. First, the nature of the Virahep-C study, including its stringent 
exclusion criteria, may have excluded individuals with lower baseline levels of self-efficacy 
(e.g., those with severe psychiatric comorbidities, alcohol or drug dependence, social 
instability, etc.). A second limitation was the missing TW24 self-efficacy data among 
Responders which may have affected TW24 analyses of missed doses and nonpersistence 
between TW24 and TW48. As these Responders had higher levels of baseline GSE, it is 
possible that their TW24 scores could have affected the TW24 analyses. Third, the lack of 
power due to the low number of nonpersistence events that occurred during the study (n=39) 
may have precluded detecting statistically significant associations between self-efficacy and 
nonpersistence. Moreover, we were unable to examine nonpersistence from weeks 24 to 48 
due to too few events. The Patient Education and Adherence intervention that was delivered 
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to all participants before and during treatment may have improved medication adherence 
and persistence during the study in all patients, limiting the number of missed doses and 
nonpersistence events and perhaps reducing potential variability in self-efficacy scores. 
Unfortunately, the study was not designed with a comparison condition to evaluate the 
benefits of such an intervention on patient self-efficacy, dose-taking behavior, or 
persistence.
Despite these limitations, the present study is the first empirical investigation of self-efficacy 
during HCV antiviral treatment. In light of the present study’s findings that aspects of self-
efficacy likely influence aspects of HCV treatment adherence, particularly among certain 
subgroups, there appears to be a fertile ground for future clinical and research endeavors to 
elucidate self-efficacy’s role during HCV treatment. Because self-efficacy is a behavioral 
construct that research has shown can be enhanced through interventions, and can improve 
health behaviors when enhanced, it is a particularly useful target for improving clinical 
outcomes. Future empirical investigations should be more inclusive of “real world” HCV 
patients, many of whom have mental health and/or substance abuse issues which likely 
impacts one’s level of self-efficacy 4, 39. These studies, within both rigorous trial settings 
and real world clinical settings, need to investigate whether: (a) self-efficacy predicts missed 
doses and nonpersistence, and (b) whether tailored interventions can bolster self-efficacy or 
reduce depression and in turn improve medication adherence and health outcomes, as shown 
in HIV populations 31. Future investigations should consider examining self-efficacy within 
the framework of an overarching health behavior model, to advance the understanding of 
how intrapersonal factors, including self-efficacy, may enable patient’s to adhere to a 
difficult treatment regimen17, 40. Lastly, future research should examine the role of self-
efficacy within the context of the newer, more complex HCV treatment regimens which 
require greater precision in dosing and introduce the possibility of viral resistance, which 
could occur if patient’s drop out of treatment too soon or fail to take their medication 
appropriately.
Conclusions
Personal, highly self-efficacious beliefs have been well-demonstrated in the broader health 
behavior literature as playing an important role in how patient’s pursue goal-oriented health 
behaviors. While the importance of self-efficacy to taking medications has been 
demonstrated in other patient populations, self-efficacy’s role in taking HCV medications 
and persisting on difficult antiviral treatment had not been investigated. The findings of this 
study provide researchers and clinicians initial insights into self-efficacy’s relationship with 
missed doses and nonpersistence during HCV treatment. This study highlights that patient 
selection and access to adherence-enhancing strategies may influence study results, and that, 
at least for HCV treatment, self-efficacy may not be as important to dose-taking behaviors, 
as it is to persistence on treatment. These initial findings lay the groundwork for further 
investigations into the relationship between self-efficacy and adherence to HCV treatment.
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Comparison of Global Self-Efficacy (GSE) Scores by Level of Depressive Symptomatology 
at Baseline (left panel, N=384) and Treatment Week 24 (right panel, N=165). Significance 
bars represent pairwise comparisons using Kruskal-Wallis test with a Bonferroni correction 
for multiple comparisons set at 0.05/3=0.0167. Among baseline participants, GSE was 
highest among those with no depressive symptomatology at baseline when compared to 
participants with mild-to-moderate (p<0.001) and severe (p<0.001) depressive symptoms, 
respectively. Among participants who continued on treatment from week 24 to 48, GSE at 
treatment week 24 was higher among those with no depressive symptoms when compared 
with those with severe depressive symptoms (p<0.001).
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Table 1
The Hepatitis C Treatment Self-Efficacy Survey
Question Stem: How confident are you that you can…
Domain 1: Communication Self-Efficacy
1 Ask your doctor things about your illness that concerns you?
2 Discuss openly with your doctor any personal problems that may be related to your illness?
3 Work out difficulties with your doctor when they arise?
Domain 2: Physical Coping Self-Efficacy
4 Keep fatigue caused by your disease from interfering with the things you want to do?
5 Keep the physical discomfort or pain of your disease from interfering with the things you want to do?
6 Keep any symptoms or health problems you have from interfering with the things you want to do?
7 Control any symptoms or health problems you have so they don’t interfere with the things you want to do?
Domain 3: Psychological Coping Self-Efficacy
8 Keep from feeling sad or down in the dumps?
9 Keep yourself from feeling lonely?
10 Do something to make yourself feel better when you are feeling lonely?
11 Do something to make yourself feel better when you are feeling discouraged?
12 Do something to make yourself feel better when you feel sad or down in the dumps?
Domain 4: Treatment Adherence Self-Efficacy
13 Inject interferon every week, exactly as directed, without ever missing a dose?
14 Take your ribavirin pills twice a day, exactly as directed, without ever missing a dose?
15 Take both medicines, always at the right time, even when feeling very tired or depressed?
16 Remember to take your medications, always at the right time, for the next 30 days?
17 Keep all your doctor visits without ever missing an appointment?
Note: Responses range from 0 (Cannot do at all) to 10 (Certain to Do). Global Self-Efficacy and sub-scale scores are calculated by averaging the 
items. Higher scores indicate higher levels of self-efficacy. Reprinted with permission from Bonner, JE, Esserman, D., and Evon, DM. Reliability 
and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. J Viral Hepat 2012 May; 19(5):316-26.
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Table 4
Baseline Self-Efficacy as a Predictor of Ribavirin Nonpersistence
Baseline to Treatment Week 24
Unadjusted (N=384) Adjusteda (N=384)
HR (95% CI) p-value HR (95% CI) p-value
Global Self-Efficacy 0.73 (0.59, 0.90) 0.004 0.77 (0.58, 1.03) 0.078
Communication Self-Efficacy 0.83 (0.70, 0.98) 0.026 0.87 (0.73, 1.04) 0.125
Physical Coping Self-Efficacy 0.86 (0.75. 0.98) 0.026 0.93 (0.79, 1.09) 0.380
Psychological Coping Self-Efficacy 0.88 (0.75, 1.03) 0.107 0.97 (0.79, 1.18) 0.745
Adherence Self-Efficacy 0.77 (0.65, 0.91) 0.002 0.78 (0.63, 0.95) 0.013
Note: HR: Hazard Ratio, calculated using Cox Proportional Hazards Model. CI: Confidence Interval.
a
Model adjusted for age, race, gender, employment status, marital status and baseline depressive symptomatology. Interpretation: when HR < 1, 
higher self-efficacy was associated with a lower risk of ribavirin nonpersistence.
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